Home / Health / FDA Approves Novel Herpes Treatment for Resistant Cases
FDA Approves Novel Herpes Treatment for Resistant Cases
9 Oct
Summary
- FDA greenlights Asahi Kasei's pritelivir for specific herpes cases.
- Drug targets herpes virus proteins, effective against resistant infections.
- Trial showed significant improvement compared to existing treatments.
On Friday, October 9th, 2026, the U.S. Food and Drug Administration (FDA) granted approval to Asahi Kasei's oral medication, pritelivir. This new drug is indicated for specific patients with weakened immune systems who have not found relief from existing antiviral treatments for persistent herpes simplex virus sores.
The development of pritelivir was spearheaded by German drugmaker Aicuris, a company acquired by Asahi Kasei in April. This innovative treatment functions by inhibiting proteins crucial for the herpes virus's genetic replication, thereby halting its multiplication. This mechanism allows pritelivir to combat infections that have developed resistance to older, first-line antiviral drugs.
These older medications require activation by a viral enzyme, and mutations can render them ineffective. Pritelivir's approval is supported by a late-stage trial involving 101 participants. The trial results indicated that 62.7% of patients treated with pritelivir experienced complete healing of their sores within 28 days, a notable increase from the 34% observed in patients receiving other treatments.
Commonly reported side effects during the trial included headache, diarrhea, nausea, reduced appetite, vomiting, and dizziness. Asahi Kasei anticipates that pritelivir could serve approximately 15,000 U.S. patients with compromised immune systems and projects peak annual sales exceeding $400 million by the mid-to-late 2030s.
